Enhanc3D Genomics, a company that focuses on creating innovative technologies to unlock the 3D spatial genome for target and biomarker discovery, has appointed Dr. Hazel Jones as its new Chief Operating Officer. Dr. Jones’s appointment is the company’s next step in broadening the application of its technology and securing strategic partnerships with pharmaceutical companies.
Dr. Jones will be responsible for managing and scaling the company’s global business operations. She will also play an essential role in delivering the company’s strategy to commercial and academic partners. Her role involves long-term strategic planning of logistics and managing alliances with stakeholders.
Dr. Jones brings a wealth of knowledge and experience to the table with executive product director of clinical data and head of business planning and operations in oncology R&D roles at AstraZeneca and head of combination therapies at Cancer Research UK.
Enhanc3D Genomics has developed a genome-wide 3D sequencing platform called GenLink3D. GenLink3D is a pipeline composed of a proprietary molecular assay with advanced algorithms and machine-learning capabilities. It provides the first genome-wide, high-resolution mapping of DNA interactions in 3D space. The company is using this technology to create an extensive database of candidate therapeutic targets for development with pharmaceutical partners.
CEO Dr. Debora Lucarelli expressed that Dr. Hazel Jones’s expertise will be invaluable to the company’s further development as they strive to establish strategic partnerships to develop its extensive database of candidate therapeutic targets and disease biomarkers. Dr. Jones’s ability to operate autonomously across large-scope projects, a deep understanding of the pharmaceutical development process and a people-centric leadership approach, will play a central role in driving operational change.
Dr. Jones said, “I’m delighted to join the team at such an exciting stage of the company’s development, and to support Enhanc3D’s vision to ultimately improve outcomes for patients through more targeted treatment options.”